Antares Pharma (ATRS) 10-Q 8 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 01, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	ATRS
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	1,016,169
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		156,407,319

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 33,418,393	$ 27,714,588
Short-term investments	9,960,479	0
Accounts receivable	9,067,689	9,073,173
Inventories	7,845,547	5,326,962
Deferred costs	893,619	1,773,446
Prepaid expenses and other current assets	1,690,036	1,376,299
Total current assets	62,875,763	45,264,468
Equipment, molds, furniture and fixtures, net	17,550,876	17,867,412
Patent rights, net	1,766,830	2,044,608
Goodwill	1,095,355	1,095,355
Other assets	53,847	53,607
Total Assets	83,342,671	66,325,450
Current Liabilities:
Accounts payable	8,478,038	7,884,983
Accrued expenses and other liabilities	6,172,077	5,872,846
Deferred revenue	3,483,297	6,149,087
Total current liabilities	18,133,412	19,906,916
Long-term debt	24,724,304
Deferred revenue – long term	200,000	1,200,000
Total liabilities	43,057,716	21,106,916
Stockholders’ Equity:
Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding
Common Stock: $0.01 par; 300,000,000 shares authorized; 156,332,319 and 155,167,677 issued and outstanding at June 30, 2017 and December 31, 2016, respectively	1,563,323	1,551,677
Additional paid-in capital	300,537,059	297,826,433
Accumulated deficit	(261,118,353)	(253,445,306)
Accumulated other comprehensive loss	(697,074)	(714,270)
Total Stockholders' Equity	40,284,955	45,218,534
Total Liabilities and Stockholders’ Equity	$ 83,342,671	$ 66,325,450

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	156,332,319	155,167,677
Common Stock, shares outstanding	156,332,319	155,167,677

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Product sales	$ 7,344,413	$ 8,690,002	$ 17,381,225	$ 19,531,049
Development revenue	4,787,672	3,267,397	6,409,549	4,365,771
Licensing revenue	1,019,040	38,721	1,037,718	89,422
Royalties	265,034	232,270	595,126	560,920
Total revenue	13,416,159	12,228,390	25,423,618	24,547,162
Cost of revenue:
Cost of product sales	3,633,218	5,216,527	9,081,509	11,464,083
Cost of development revenue	1,983,171	2,101,571	2,754,646	2,629,756
Total cost of revenue	5,616,389	7,318,098	11,836,155	14,093,839
Gross profit	7,799,770	4,910,292	13,587,463	10,453,323
Operating expenses:
Research and development	3,159,363	3,948,020	6,245,644	9,596,049
Selling, general and administrative	7,360,010	7,014,520	14,827,265	14,617,698
Total operating expenses	10,519,373	10,962,540	21,072,909	24,213,747
Operating loss	(2,719,603)	(6,052,248)	(7,485,446)	(13,760,424)
Other income (expense)	(120,341)	(9,215)	(90,415)	42,851
Net loss	$ (2,839,944)	$ (6,061,463)	$ (7,575,861)	$ (13,717,573)
Basic and diluted net loss per common share	$ (0.02)	$ (0.04)	$ (0.05)	$ (0.09)
Basic and diluted weighted average common shares outstanding	155,926,149	154,936,096	155,572,562	154,897,089

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (2,839,944)	$ (6,061,463)	$ (7,575,861)	$ (13,717,573)
Foreign currency translation adjustment	12,855	(5,755)	17,196	(10,452)
Comprehensive loss	$ (2,827,089)	$ (6,067,218)	$ (7,558,665)	$ (13,728,025)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (7,575,861)	$ (13,717,573)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,283,592	1,277,277
Depreciation and amortization	971,489	891,388
Loss on disposal of equipment		17,785
Write-off of capitalized patent costs	45,600
Accretion of interest expense	13,980
Amortization of debt issuance costs	3,863
Amortization of premiums and discounts on investment securities	(133)	7,798
Changes in operating assets and liabilities:
Accounts receivable	9,663	(2,358,302)
Inventories	(2,518,585)	(1,734,536)
Prepaid expenses and other assets	(309,507)	582,241
Deferred costs	879,827	(942,063)
Accounts payable	721,038	5,073,875
Accrued expenses and other current liabilities	48,877	369,693
Deferred revenue	(3,668,284)	1,849,291
Net cash used in operating activities	(10,094,441)	(8,683,126)
Cash flows from investing activities:
Purchase of investment securities	(9,963,978)
Purchases of equipment, molds, furniture and fixtures	(529,239)	(2,555,174)
Additions to patent rights	(56,970)	(39,019)
Proceeds from maturities of investment securities		6,000,000
Net cash provided by (used in) investing activities	(10,550,187)	3,405,807
Cash flows from financing activities:
Proceeds from issuance of long-term debt	25,000,000
Payment of debt issuance costs	(241,431)
Proceeds from exercise of stock options	1,590,204
Taxes paid related to net share settlement of equity awards	(248,709)	(64,096)
Net cash provided by (used in) financing activities	26,348,773	(64,096)
Effect of exchange rate changes on cash	(340)	1,947
Net increase (decrease) in cash	5,703,805	(5,339,468)
Cash and cash equivalents:
Beginning of period	27,714,588	32,898,676
End of period	33,418,393	27,559,208
Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	271,959	1,293,346
Additions to patent rights recorded in accounts payable and accrued expenses	18,313	$ 32,586
Supplemental disclosure of non-cash financing activities:
Tax witholding on net settled equity awards included in accrued liabilities	248,709
Debt issuance costs included in accounts payable and accrued expenses	$ 52,108

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Antares Pharma, Inc. (“Antares” or the “Company”) is an emerging, specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures, for itself or with partners, novel therapeutic products using its advanced drug delivery technology to enhance the existing drug compounds and delivery methods. The subcutaneous injection technology platforms include the VIBEX ® The Company markets and sells its proprietary product OTREXUP ® ® ® The Company, with its commercialization partner Teva, launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. In December 2015, the Company received FDA approval for an Abbreviated New Drug Application (“ANDA”) for 4 mg/0.5 mL and 6 mg/0.5 mL single-dose prefilled syringe auto-injectors, a generic equivalent to Imitrex ® ® ® The Company is developing XYOSTED TM

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission's Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes thereto should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. Investments The primary objectives of the Company’s investment policy are to protect principal, maintain adequate liquidity and maximize returns. The Company’s investments consist of U.S. Treasury bills and government agency notes that are classified as held-to-maturity because the Company has the intent and ability to hold the securities to maturity. Investments with maturities of one year or less are classified as short-term. The securities are carried at their amortized cost and the fair value is determined by quoted market prices. At June 30, 2017, the Company’s investments had a carrying value of $9,960,479, which approximated fair value. The Company held no investments as of December 31, 2016. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $750,000 and $900,000 at June 30, 2017 and December 31, 2016, respectively. Inventories consist of the following: June 30, December 31, 2017 2016 Inventories: Raw material $ 85,344 $ 142,491 Work in process 5,656,453 2,429,075 Finished goods 2,103,750 2,755,396 $ 7,845,547 $ 5,326,962 OTREXUP ® The Company began detailing OTREXUP ® ® Prior to the first quarter of 2017, the Company could not reliably estimate expected returns of OTREXUP ® ® In the first quarter of 2017, the Company determined it had developed sufficient historical information to reasonably estimate future returns of OTREXUP ® ® Product sales revenue for OTREXUP ® Product Sales Allowances The Company recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, it may be necessary to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Product sales allowances include: Wholesaler Distribution Fees . Distribution fees are paid to certain wholesale distributors based on contractually determined rates. The Company accrues the fee on shipment to the respective wholesale distributors and recognizes the fee as a reduction of revenue in the same period the related revenue is recognized. Prompt Pay Discounts . The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Chargebacks . The Company provides discounts to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. Rebates . The Company participates in certain rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized. Patient Discount Programs . The Company offers discount card programs to patients for OTREXUP ®

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Long-Term Debt	3 . Long-Term Debt On June 6, 2017, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc., for a term loan of up to $35,000,000 (the “Term Loan”), the proceeds of which are to be used for working capital and general corporate purposes. The first advance of $25,000,000 was funded upon execution of the Loan Agreement on June 6, 2017. Under the terms of the Loan Agreement, the Company may, but is not obligated to, request one or more additional advances of at least $5,000,000 not to exceed $10,000,000 in the aggregate, subject to the Company achieving certain corporate milestones and satisfying customary conditions. The Company must exercise its option to request additional advances prior to September 30, 2018. The Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, and will mature on July 1, 2022. The Term Loan accrues interest at a calculated prime-based variable rate with a maximum interest rate of 9.50%. As of June 30, 2017, the interest rate was 8.75%. Payments under the Loan Agreement are interest only until the first principal payment is due on August 1, 2019, provided that the interest only period may be extended to February 1, 2020 if the Company achieves certain corporate milestones. The Loan Agreement also requires the Company to pay a fee equal to 4.25% of the total original principal amount of all term loan advances (“End of Term Charge”), which is due upon repayment of the Term Loan at either maturity or earlier repayment, and imposes a prepayment fee of 1.0% to 3.0% if any or all of the balance is prepaid prior to the maturity date. As of June 30, 2017, the carrying value of the Term Loan was $24,724,304, which consisted of the $25,000,000 principal balance outstanding and the End of Term Charge accrual of $13,980, less unamortized debt issuance costs of $289,676. The Company incurred debt issuance costs that, along with the End of Term Charge, are being amortized/accrued to interest expense over the term of the Term Loan using the effective interest method. Future principal payments under the term loan, including the End of Term Charge, are as follows: June 30, 2017 2017 $ — 2018 — 2019 3,086,729 2020 7,883,810 2021 8,595,931 Thereafter 6,496,030 $ 26,062,500 The Company believes that the carrying value of the Term Loan approximates its fair value based on the borrowing rates currently available for loans with similar terms.

Share Based Compensation

Share Based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation	4 . Share-Based Compensation The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The maximum number of shares authorized for issuance under the amended and restated Plan is 32,200,000 and the maximum number of shares of stock that may be granted to any one employee for qualified performance-based compensation during a calendar year is 4,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is ten years and the options typically vest in quarterly installments over a three-year period with a minimum vesting period of one year. As of June 30, 2017, the Plan had approximately 6,500,000 shares available for grant. Stock option exercises are satisfied through the issuance of new shares. Stock Options The following is a summary of stock option activity under the Plan as of and for the six months ended June 30, 2017: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2016 11,313,909 $ 1.84 Granted 2,803,667 2.65 Exercised (969,108 ) 1.64 Cancelled/Forfeited (674,619 ) 2.49 Outstanding at June 30, 2017 12,473,849 2.01 7.4 $ 15,597,050 Exercisable at June 30, 2017 7,614,437 $ 1.94 6.2 $ 10,232,347 The per share weighted average fair values of all options granted during the six months ended June 30, 2017 and 2016 were estimated as $1.37 and $0.54, respectively, on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock price. The weighted average expected life is based on both historical and anticipated employee behavior. June 30, 2017 2016 Risk-free interest rate 1.8% 1.3% Annualized volatility 53.4% 51.6% Weighted average expected life, in years 6.0 6.0 Expected dividend yield 0.0% 0.0% During the six months ended June 30, 2017, stock option exercises resulted in cash proceeds to the Company of $1,590,204 and the issuance of 969,108 shares of common stock. No stock options were exercised during the six months ended June 30, 2016. The Company recognized $987,603 and $1,067,047 of compensation expense related to stock options for the six months ended June 30, 2017 and 2016, respectively, and $520,161 and $504,814 for the three months ended June 30, 2017 and 2016, respectively. As of June 30, 2017, there was approximately $4,900,000 of total unrecognized compensation cost related to non-vested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.2 years. Long Term Incentive Program The Company’s Board of Directors has approved a long term incentive program (“LTIP”) for the benefit of the Company’s senior executives. Pursuant to the LTIP, the Company’s senior executives have been awarded stock options, restricted stock units (“RSU”) and performance stock units (“PSU”) with targeted values based on values granted to similarly situated senior executives in the Company’s peer group. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The RSUs vest in three equal annual installments. The PSU awards made to the senior executives vest and convert into shares of the Company’s common stock based on the Company’s attainment of certain performance goals as established by the Company’s Board of Directors over a performance period, which is typically three to five years. The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2016 1,347,289 $ 1.50 822,658 $ 1.39 Granted 649,180 2.81 649,180 2.66 Vested/settled — (287,508 ) 1.49 Forfeited/expired (502,308 ) 2.16 (67,464 ) 1.70 Outstanding at June 30, 2017 1,494,161 $ 2.04 1,116,866 $ 2.08 In 2017, 2016 and 2015, the LTIP awards include PSUs that may be earned based on the Company’s total shareholder return (“TSR”) relative to the Nasdaq Biotechnology Index (“NBI”) at the end of the performance period. The performance period is January 1, 2015 to December 31, 2017 for the 2015 award, January 1, 2016 to December 31, 2018 for the 2016 award and January 1, 2017 to December 31, 2019 for the 2017 award. Depending on the outcome of the performance goal, a recipient may ultimately earn a number of shares greater or less than their target number of shares granted, ranging from 0% to 150% of the PSUs granted. The fair values of the TSR PSUs granted was determined using a Monte Carlo simulation and utilized the following inputs and assumptions: 2017 Award 2016 Award 2015 Award Closing stock price on grant date $ 2.66 $ 1.12 $ 2.18 Performance period starting price $ 2.17 $ 1.29 $ 2.52 Term of award (in years) 2.57 2.58 2.59 Volatility 54.6 % 70.1 % 60.5 % Risk-free interest rate 1.39 % 0.97 % 0.83 % Expected dividend yield 0.00 % 0.00 % 0.00 % Fair value per TSR PSU $ 3.10 $ 1.25 $ 1.71 The performance period starting price is measured as the average closing price over the last 20 trading days prior to the performance period start. The Monte Carlo simulation model also assumed correlations of returns of the prices of the Company’s common stock and the common stocks of the NBI companies and stock price volatilities of the NBI companies. The fair value of the target number of shares that can be earned under the TSR PSUs is being recognized as compensation expense over the performance period. In connection with PSU awards, the Company recognized compensation expense of $88,296 and $8,294 for the six months ended June 30, 2017 and 2016, respectively. Compensation expense recognized in connection with RSU awards was $207,693 and $201,936 for the six months ended June 30, 2017 and 2016, respectively. Shares issued in connection with LTIP awards that vested in the six months ended June 30, 2017 and 2016 were net-share settled such that the Company withheld shares with a value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld to satisfy tax obligations were 97,586 and 65,575 in the six months ended June 30, 2017 and 2016, respectively, and were based on the fair value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $248,709 and $64,096 in the six months ended June 30, 2017 and 2016, respectively, and are reflected as a financing activity within the consolidated statements of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.

Significant Customers and Conce

Significant Customers and Concentrations of Risk	6 Months Ended
	Jun. 30, 2017
Risks And Uncertainties [Abstract]
Significant Customers and Concentrations of Risk	5 . Significant Customers and Concentrations of Risk Revenues by customer location are summarized as follows: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 United States of America $ 12,167,166 $ 11,024,136 $ 22,835,189 $ 21,594,742 Europe 1,112,185 1,047,250 2,267,629 2,614,591 Other 136,808 157,004 320,800 337,829 $ 13,416,159 $ 12,228,390 $ 25,423,618 $ 24,547,162 Significant customers from which the Company derived 10% or more of total revenue are as follows: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Teva $ 4,417,179 $ 6,505,126 $ 9,380,253 $ 12,990,976 AMAG 3,803,460 410,919 4,570,573 905,882 McKesson 1,769,827 1,846,255 3,993,842 3,555,549 Ferring 987,103 1,055,767 2,294,597 2,714,389 AmerisourceBergen 1,444,397 1,354,801 2,852,745 2,501,887

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Share	6 . Net Loss Per Share Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock. Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share because their effect was anti-dilutive totaled 15,084,876 and 15,017,289 at June 30, 2017 and 2016, respectively.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2017
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements	7 . Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-11, Simplifying the Measurement of Inventory In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting “ In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Recent Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers The Company continues to monitor and evaluate the impact the adoption of this standard will have on its consolidated financial statements and has performed an initial review of its major contracts with customers. Based on the initial reviews, the Company believes the adoption of the new standard may accelerate the timing of revenue recognition for product sales and development revenue under certain license, development and supply agreements, and will require management to estimate and potentially recognize certain variable revenue streams such as royalties and profit sharing arrangements earlier at an amount it believes will not be subject to significant reversal. The Company anticipates adopting the new revenue recognition standard on the effective date of January 1, 2018 utilizing the modified retrospective method of adoption, under which the cumulative effect of the change is recognized as an adjustment to the opening balance of the accumulated deficit within the consolidated balance sheet, and prior reporting periods are not retrospectively adjusted. No significant changes to business processes or systems are currently expected to be necessary. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Basis of Presentation and Sig14

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Investments	Investments The primary objectives of the Company’s investment policy are to protect principal, maintain adequate liquidity and maximize returns. The Company’s investments consist of U.S. Treasury bills and government agency notes that are classified as held-to-maturity because the Company has the intent and ability to hold the securities to maturity. Investments with maturities of one year or less are classified as short-term. The securities are carried at their amortized cost and the fair value is determined by quoted market prices. At June 30, 2017, the Company’s investments had a carrying value of $9,960,479, which approximated fair value. The Company held no investments as of December 31, 2016.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $750,000 and $900,000 at June 30, 2017 and December 31, 2016, respectively. Inventories consist of the following: June 30, December 31, 2017 2016 Inventories: Raw material $ 85,344 $ 142,491 Work in process 5,656,453 2,429,075 Finished goods 2,103,750 2,755,396 $ 7,845,547 $ 5,326,962
Revenue Recognition	OTREXUP ® The Company began detailing OTREXUP ® ® Prior to the first quarter of 2017, the Company could not reliably estimate expected returns of OTREXUP ® ® In the first quarter of 2017, the Company determined it had developed sufficient historical information to reasonably estimate future returns of OTREXUP ® ® Product sales revenue for OTREXUP ® Product Sales Allowances The Company recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, it may be necessary to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Product sales allowances include: Wholesaler Distribution Fees . Distribution fees are paid to certain wholesale distributors based on contractually determined rates. The Company accrues the fee on shipment to the respective wholesale distributors and recognizes the fee as a reduction of revenue in the same period the related revenue is recognized. Prompt Pay Discounts . The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Chargebacks . The Company provides discounts to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. Rebates . The Company participates in certain rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized. Patient Discount Programs . The Company offers discount card programs to patients for OTREXUP ®
Recent Accounting Pronouncements	Accounting Pronouncements Recently Adopted In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-11, Simplifying the Measurement of Inventory In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting “ In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Recent Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers The Company continues to monitor and evaluate the impact the adoption of this standard will have on its consolidated financial statements and has performed an initial review of its major contracts with customers. Based on the initial reviews, the Company believes the adoption of the new standard may accelerate the timing of revenue recognition for product sales and development revenue under certain license, development and supply agreements, and will require management to estimate and potentially recognize certain variable revenue streams such as royalties and profit sharing arrangements earlier at an amount it believes will not be subject to significant reversal. The Company anticipates adopting the new revenue recognition standard on the effective date of January 1, 2018 utilizing the modified retrospective method of adoption, under which the cumulative effect of the change is recognized as an adjustment to the opening balance of the accumulated deficit within the consolidated balance sheet, and prior reporting periods are not retrospectively adjusted. No significant changes to business processes or systems are currently expected to be necessary. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Basis of Presentation and Sig15

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Inventories	Inventories consist of the following: June 30, December 31, 2017 2016 Inventories: Raw material $ 85,344 $ 142,491 Work in process 5,656,453 2,429,075 Finished goods 2,103,750 2,755,396 $ 7,845,547 $ 5,326,962

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of Future Principal Payments under Term Loan, Including End of Term Charge	Future principal payments under the term loan, including the End of Term Charge, are as follows: June 30, 2017 2017 $ — 2018 — 2019 3,086,729 2020 7,883,810 2021 8,595,931 Thereafter 6,496,030 $ 26,062,500

Share Based Compensation (Table

Share Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Summary of Stock Option Activity	The following is a summary of stock option activity under the Plan as of and for the six months ended June 30, 2017: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2016 11,313,909 $ 1.84 Granted 2,803,667 2.65 Exercised (969,108 ) 1.64 Cancelled/Forfeited (674,619 ) 2.49 Outstanding at June 30, 2017 12,473,849 2.01 7.4 $ 15,597,050 Exercisable at June 30, 2017 7,614,437 $ 1.94 6.2 $ 10,232,347
Assumptions Used in Fair Value Measurement of Options Granted	June 30, 2017 2016 Risk-free interest rate 1.8% 1.3% Annualized volatility 53.4% 51.6% Weighted average expected life, in years 6.0 6.0 Expected dividend yield 0.0% 0.0%
Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program	The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2016 1,347,289 $ 1.50 822,658 $ 1.39 Granted 649,180 2.81 649,180 2.66 Vested/settled — (287,508 ) 1.49 Forfeited/expired (502,308 ) 2.16 (67,464 ) 1.70 Outstanding at June 30, 2017 1,494,161 $ 2.04 1,116,866 $ 2.08
Performance Stock Units [Member]
Assumptions Used in Fair Value Measurement of Options Granted	The fair values of the TSR PSUs granted was determined using a Monte Carlo simulation and utilized the following inputs and assumptions: 2017 Award 2016 Award 2015 Award Closing stock price on grant date $ 2.66 $ 1.12 $ 2.18 Performance period starting price $ 2.17 $ 1.29 $ 2.52 Term of award (in years) 2.57 2.58 2.59 Volatility 54.6 % 70.1 % 60.5 % Risk-free interest rate 1.39 % 0.97 % 0.83 % Expected dividend yield 0.00 % 0.00 % 0.00 % Fair value per TSR PSU $ 3.10 $ 1.25 $ 1.71

Significant Customers and Con18

Significant Customers and Concentrations of Risk (Tables)	6 Months Ended
	Jun. 30, 2017
Risks And Uncertainties [Abstract]
Summary of Revenues by Customer Location	Revenues by customer location are summarized as follows: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 United States of America $ 12,167,166 $ 11,024,136 $ 22,835,189 $ 21,594,742 Europe 1,112,185 1,047,250 2,267,629 2,614,591 Other 136,808 157,004 320,800 337,829 $ 13,416,159 $ 12,228,390 $ 25,423,618 $ 24,547,162
Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue	Significant customers from which the Company derived 10% or more of total revenue are as follows: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Teva $ 4,417,179 $ 6,505,126 $ 9,380,253 $ 12,990,976 AMAG 3,803,460 410,919 4,570,573 905,882 McKesson 1,769,827 1,846,255 3,993,842 3,555,549 Ferring 987,103 1,055,767 2,294,597 2,714,389 AmerisourceBergen 1,444,397 1,354,801 2,852,745 2,501,887

Basis of Presentation and Sig19

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Carrying value of investments	$ 9,960,479	$ 0	$ 9,960,479		$ 9,960,479
Inventory reserve	750,000	900,000	750,000		750,000
Product revenue			$ 7,344,413	$ 8,690,002	17,381,225	$ 19,531,049
Cash discount to incentive for prompt payment							2.00%
OTREXUP [Member]
Summary Of Significant Accounting Policies [Line Items]
Product revenue					8,487,163
Revenue recognized, not recognized previously					1,297,054
Related product costs recognized					254,425
Revenue Recognition, decrease in net loss					$ 1,042,629
Estimated product returns reserve	630,000	0
Product sales allowances	$ 2,081,476	$ 1,540,488
OTREXUP [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition, decrease in net loss per share					$ 0.01

Basis of Presentation and Sig20

Basis of Presentation and Significant Accounting Policies - Inventories (Detail) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Inventories:
Raw material	$ 85,344	$ 142,491
Work in process	5,656,453	2,429,075
Finished goods	2,103,750	2,755,396
Inventory, Total	$ 7,845,547	$ 5,326,962

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Jun. 06, 2017	Jun. 30, 2017
Debt Instrument [Line Items]
Advance of funded upon execution of loan agreement		$ 25,000,000
Carrying value of long term debt		$ 24,724,304
Hercules Capital, Inc [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Long-tem debt, face amount	$ 35,000,000
Advance of funded upon execution of loan agreement	$ 25,000,000
Debt Instrument, covenant description		Under the terms of the Loan Agreement, the Company may, but is not obligated to, request one or more additional advances of at least $5,000,000 not to exceed $10,000,000 in the aggregate, subject to the Company achieving certain corporate milestones and satisfying customary conditions.
Debt instrument, maturity date Description		The Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, and will mature on July 1, 2022
Debt instrument, maturity date		Jul. 1, 2022
Debt Instrument, interest rate		8.75%
Debt instrument, payment terms		Payments under the Loan Agreement are interest only until the first principal payment is due on August 1, 2019, provided that the interest only period may be extended to February 1, 2020 if the Company achieves certain corporate milestones.
Debt instrument, first pricipal payment due date		Aug. 1, 2019
Debt instrument, first pricipal payment may be extended date		Feb. 1, 2020
Percentage of loan fee on original principal amount		4.25%
Carrying value of long term debt		$ 24,724,304
Principal balance outstanding		25,000,000
Term charge accrual		13,980
Unamortized debt issuance costs		$ 289,676
Hercules Capital, Inc [Member] | Term Loan [Member] | Prime Based Variable Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, variable interest rate	9.50%
Hercules Capital, Inc [Member] | Term Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Prepayment fee percentage on principal loan prepaid		1.00%
Hercules Capital, Inc [Member] | Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Prepayment fee percentage on principal loan prepaid		3.00%
Hercules Capital, Inc [Member] | Term Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Amount of additional advances Company may request	$ 5,000,000
Hercules Capital, Inc [Member] | Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Amount of additional advances Company may request	$ 10,000,000

Long-Term Debt - Schedule of Fu

Long-Term Debt - Schedule of Future Principal Payments under Term Loan, Including End of Term Charge (Detail)	Jun. 30, 2017USD ($)
Debt Disclosure [Abstract]
2,019	$ 3,086,729
2,020	7,883,810
2,021	8,595,931
Thereafter	6,496,030
Long-term debt	$ 26,062,500

Share Based Compensation - Addi

Share Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from the issuance of stock options			$ 1,590,204
Shares withheld to meet employees' minimum statutory income tax obligation			97,586	65,575
Payments for the employees' minimum statutory income tax obligation			$ 248,709	$ 64,096
Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized	32,200,000		32,200,000
Maximum number of shares of stock granted to one participant			4,000,000
Minimum percentage of exercise price			100.00%
Shares available for grant under the plan	6,500,000		6,500,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Per share weighted average fair values of options granted			$ 1.37	$ 0.54
Proceeds from the issuance of stock options			$ 1,590,204
Exercise of options, shares			969,108	0
Recognized compensation cost related to shares of stock granted	$ 520,161	$ 504,814	$ 987,603	$ 1,067,047
Unrecognized compensation cost related to nonvested outstanding stock awards	$ 4,900,000		$ 4,900,000
Weighted average period expected to be recognized			2 years 2 months 12 days
Stock Options [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted			10 years
Vesting period			3 years
Stock Options [Member] | Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted			10 years
Vesting period			3 years
Stock Options [Member] | Minimum [Member] | Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Restricted Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Recognized compensation cost related to shares of stock granted			$ 207,693	201,936
Performance Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized compensation cost related to shares of stock granted			$ 88,296	$ 8,294
Performance Stock Units [Member] | Minimum [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Share based compensation award percentage			0.00%
Performance Stock Units [Member] | Maximum [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			5 years
Share based compensation award percentage			150.00%

Share Based Compensation - Summ

Share Based Compensation - Summary of Stock Option Activity (Detail)	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Stockholders Equity Note [Abstract]
Number of Shares Outstanding, Beginning Balance | shares	11,313,909
Number of Shares Granted | shares	2,803,667
Number of Shares Exercised | shares	(969,108)
Number of Shares Cancelled/Forfeited | shares	(674,619)
Number of Shares Outstanding, Ending Balance | shares	12,473,849
Number of Shares Exercisable, Ending Balance | shares	7,614,437
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 1.84
Weighted Average Exercise Price Granted | $ / shares	2.65
Weighted Average Exercise Price Exercised | $ / shares	1.64
Weighted Average Exercise Price Cancelled/Forfeited | $ / shares	2.49
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	2.01
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 1.94
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	7 years 4 months 24 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	6 years 2 months 12 days
Aggregate Intrinsic Value Outstanding, Ending Balance | $	$ 15,597,050
Aggregate Intrinsic Value Exercisable, Ending Balance | $	$ 10,232,347

Share Based Compensation - Assu

Share Based Compensation - Assumptions Used in Fair Value Measurement of Options Granted (Detail)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Stockholders Equity Note [Abstract]
Risk-free interest rate	1.80%	1.30%
Annualized volatility	53.40%	51.60%
Weighted average expected life, in years	6 years	6 years
Expected dividend yield	0.00%	0.00%

Share Based Compensation - Sche

Share Based Compensation - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	1,347,289
Number of Shares, Granted | shares	649,180
Number of Shares, Forfeited/expired | shares	(502,308)
Number of Shares, Ending Balance | shares	1,494,161
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 1.50
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.81
Weighted Average Grant Date Fair Value, Forfeited/expired | $ / shares	2.16
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.04
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	822,658
Number of Shares, Granted | shares	649,180
Number of Shares, Vested/settled | shares	(287,508)
Number of Shares, Forfeited/expired | shares	(67,464)
Number of Shares, Ending Balance | shares	1,116,866
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 1.39
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.66
Weighted Average Grant Date Fair Value, Vested/settled | $ / shares	1.49
Weighted Average Grant Date Fair Value, Forfeited/expired | $ / shares	1.70
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.08

Share Based Compensation - Fair

Share Based Compensation - Fair Value of PSUs Granted Determined Using Monte Carlo Simulation (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award (in years)	6 years	6 years
Volatility	53.40%	51.60%
Risk-free interest rate	1.80%	1.30%
Expected dividend yield	0.00%	0.00%
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing stock price on grant date	$ 2.66	$ 1.12	$ 2.18
Performance period starting price	$ 2.17	$ 1.29	$ 2.52
Term of award (in years)	2 years 6 months 25 days	2 years 6 months 29 days	2 years 7 months 2 days
Volatility	54.60%	70.10%	60.50%
Risk-free interest rate	1.39%	0.97%	0.83%
Expected dividend yield	0.00%	0.00%	0.00%
Fair value per TSR PSU	$ 3.10	$ 1.25	$ 1.71

Significant Customers and Con28

Significant Customers and Concentrations of Risk - Summary of Revenues by Customer Location (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Concentration Risk [Line Items]
Total revenues	$ 13,416,159	$ 12,228,390	$ 25,423,618	$ 24,547,162
United States of America [Member]
Concentration Risk [Line Items]
Total revenues	12,167,166	11,024,136	22,835,189	21,594,742
Europe [Member]
Concentration Risk [Line Items]
Total revenues	1,112,185	1,047,250	2,267,629	2,614,591
Other [Member]
Concentration Risk [Line Items]
Total revenues	$ 136,808	$ 157,004	$ 320,800	$ 337,829

Significant Customers and Con29

Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Concentration Risk [Line Items]
Total revenues	$ 13,416,159	$ 12,228,390	$ 25,423,618	$ 24,547,162
Teva [Member]
Concentration Risk [Line Items]
Total revenues	4,417,179	6,505,126	9,380,253	12,990,976
AMAG [Member]
Concentration Risk [Line Items]
Total revenues	3,803,460	410,919	4,570,573	905,882
McKesson [Member]
Concentration Risk [Line Items]
Total revenues	1,769,827	1,846,255	3,993,842	3,555,549
Ferring [Member]
Concentration Risk [Line Items]
Total revenues	987,103	1,055,767	2,294,597	2,714,389
AmerisourceBergen [Member]
Concentration Risk [Line Items]
Total revenues	$ 1,444,397	$ 1,354,801	$ 2,852,745	$ 2,501,887

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share	15,084,876	15,017,289

Recent Accounting Pronounceme31

Recent Accounting Pronouncements - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017USD ($)
ASU 2016-09 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Cumulative effect adjustment to accumulated deficit and additional paid-in capital	$ 97,000